Evaluation of Alerts in Promoting Bone Densitometry Scans
NCT ID: NCT04955652
Last Updated: 2022-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2022-03-31
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Patient Activation After DXA Result Notification
NCT01507662
Clinical Evaluation Of An X-Ray Bone Densitometer:Use Of DXA Technology For Precise Assessment Of Human Body Composition
NCT02965742
Bone Health Management for Women Diagnosed With Breast Cancer
NCT02484131
Salivary-based Bone Loss Marker Detection Platform for Point-of-care Screening - Phase II Study
NCT02315248
A Randomized Controlled Trial of a Bone Density Decision Aide
NCT00285168
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For this evaluation, the investigators will randomly assign (by odd and even MRN) half of patients who need DXA scans to go through standard care (including the single-click BPA) and half of patients to have no BPA shown to their provider, but only the health maintenance topic and actionable Storyboard alert. This evaluation will help the investigators determine whether redundant, more traditional alerts such as BPAs are helpful or can be removed from alerts for DXA scans.
The randomization of patients to different alert conditions will be in place until 4,200 participants have been reached (estimated sample to detect 4% absolute difference, rounded to nearest hundred) or 6 months, whichever comes first. To account for delays in updating clinical databases, the outcome data will pulled 3 months after each encounter (for a maximum study period of 9 months).
The main analysis will use a logistic regression to compare the two groups. Exploratory analyses will also examine the time from order to completion to examine any effect on timing between arms. Another set of exploratory analyses will also examine the number of other BPAs firing to see if alert fatigue influenced the number of orders or completions or interacted with the experimental conditions.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard of Care
A health maintenance topic, actionable sidebar item, and a single-click best practice alert are presented.
Health Maintenance Topic
Alert
Actionable Sidebar Item
Alert
Best Practice Alert
Alert
Silent Best Practice Alert
A health maintenance topic and an actionable sidebar item are presented. The best practice alert is set to be silent and will not appear in the patient's chart.
Health Maintenance Topic
Alert
Actionable Sidebar Item
Alert
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Health Maintenance Topic
Alert
Actionable Sidebar Item
Alert
Best Practice Alert
Alert
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Records indicate patient is due for a bone densitometry scan (generally, a high-risk patient that requires this scan or age 65 and older)
Exclusion Criteria
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Geisinger Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amir Goren
Program Director, Behavioral Insights Team
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amir Goren, PhD
Role: PRINCIPAL_INVESTIGATOR
Program Director, Behavioral Insights Team
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-0996
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.